Abstract
Alzheimer's disease (AD) is a multi factorial disease, related to the loss of neurons and synapses in cerebral cortex and subcortical structures, leading to degenerative changes and atrophy. Despite abundance of facts related to AD and its pathology, the only drugs used in the prevention and treatment are those from the cholinesterase inhibitors group. However, there is growing evidence that a non-classical therapeutic approach in the treatment of AD has beneficial effects. In this review we summarized recent literature data related to the non-classical drugs for the treatment of AD predominantly used in clinical testing, such as amyloid aggregation inhibitors, beta-sheet breakers, antioxidants, estrogens and immunotherapeutics.
Keywords: Amyloid aggregation inhibitors, antioxidants, beta-sheet breakers, estrogens, immunotherapeutic Abeta, neurodegeneration.
Letters in Drug Design & Discovery
Title:Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
Volume: 12 Issue: 2
Author(s): Vladan Bajic, Biljana Spremo-Potparevic, Lada Zivkovic, Emina Sudar, Sonja Zafirovic, Milan Obradovic and Esma R. Isenovic
Affiliation:
Keywords: Amyloid aggregation inhibitors, antioxidants, beta-sheet breakers, estrogens, immunotherapeutic Abeta, neurodegeneration.
Abstract: Alzheimer's disease (AD) is a multi factorial disease, related to the loss of neurons and synapses in cerebral cortex and subcortical structures, leading to degenerative changes and atrophy. Despite abundance of facts related to AD and its pathology, the only drugs used in the prevention and treatment are those from the cholinesterase inhibitors group. However, there is growing evidence that a non-classical therapeutic approach in the treatment of AD has beneficial effects. In this review we summarized recent literature data related to the non-classical drugs for the treatment of AD predominantly used in clinical testing, such as amyloid aggregation inhibitors, beta-sheet breakers, antioxidants, estrogens and immunotherapeutics.
Export Options
About this article
Cite this article as:
Bajic Vladan, Spremo-Potparevic Biljana, Zivkovic Lada, Sudar Emina, Zafirovic Sonja, Obradovic Milan and Isenovic R. Esma, Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review, Letters in Drug Design & Discovery 2015; 12(2) . https://dx.doi.org/10.2174/1570180811666140909010803
DOI https://dx.doi.org/10.2174/1570180811666140909010803 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Amyloid Treatments in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
Current Alzheimer Research Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice
Current Alzheimer Research Immunotherapy for Conformational Diseases
Current Pharmaceutical Design Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Serial Analysis of Gene Expression in Eukaryotic Pathogens
Infectious Disorders - Drug Targets Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?
Current Alzheimer Research The Neonatal Immune System: General Concepts and Clinical Correlations
Current Immunology Reviews (Discontinued) Drug Effects on Drug Targets: Inhibition of Enzymes by Neuroleptics, Antimycotics,Antibiotics and Other Drugs on Human Pathogenic Amoebas and their Antiproliferative Effects
Recent Patents on Anti-Infective Drug Discovery Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Current Alzheimer Research Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery Applied Proteomics in Companion Animal Medicine
Current Proteomics Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment
Current Pharmaceutical Design The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease
Current Neuropharmacology Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Current Pharmaceutical Design Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry